An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A short video or article compared weight loss results from three drugs: retatrutide, tirzepatide, and semaglutide. It’s basically a side-by-side look at how much weight people lost on each medicine, probably using results from clinical trials. The piece is a comparison, not new research, so it’s summarizing data rather than announcing a brand-new study. Retatrutide, tirzepatide, and semaglutide are all drugs that act like natural hormones in the body that regulate appetite and digestion. Semaglutide is the ingredient in Ozempic and Wegovy and copies a gut hormone that helps you feel full and slows stomach emptying. Tirzepatide (brand name Zepbound or Mounjaro depending on approval and use) hits two of those hormone receptors at once, boosting the appetite-suppressing signal. Retatrutide is newer and targets three related receptors, so the idea is it might suppress appetite and change metabolism even more strongly. What the comparison likely shows is numerical weight-loss percentages from the trials: semaglutide gives solid weight loss, tirzepatide generally more, and retatrutide — from early data — might show even larger drops. But these are trial results, not real-world guarantees. The studies differ in size, duration, and who was enrolled (some include people with obesity, others include type 2 diabetes), so you can’t directly compare numbers as if they came from one head-to-head experiment. Early retatrutide data are promising but usually come from smaller or shorter trials than the large semaglutide and tirzepatide studies. Why this matters is practical: obesity is common and these drugs can change how much people eat and how their bodies handle weight. If retatrutide really delivers bigger weight loss safely, it could offer a new option for people struggling with obesity or related health problems like diabetes. That could mean fewer obesity-related complications and more effective medical weight management for some patients. For a regular person, it’s a signal that better pharmaceutical tools are coming, but it doesn’t mean instant, risk-free fixes. Caveats are important. Bigger weight loss in trials doesn’t guarantee long-term safety or effectiveness in everyone. Side effects for this class of drugs commonly include nausea, diarrhea, and stomach upset; there are also concerns about pancreatitis and gallbladder issues in some cases. Retatrutide is newer, so long-term risks and real-world experience are limited. These drugs are prescription medications; who should or shouldn’t use them is a medical decision. Also, trial results can be reported differently, so headlines comparing percentages can over-simplify the science. Bottom line: Early comparisons suggest a progression from semaglutide to tirzepatide to retatrutide in potential weight loss, but differences in study design and limited long-term data mean it’s too soon to pick a clear winner for everyday use.
Source: Diario AS